-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

652.O1.6 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Monoclonal Gammopathies of Determined Significance: What We Have and What We Want

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Epidemiology, Clinical Research, Plasma Cell Disorders, Diseases, Lymphoid Malignancies
Saturday, December 11, 2021: 12:00 PM-1:30 PM
Georgia Ballroom 1-3 (Georgia World Congress Center)
Moderators:
Angela Dispenzieri, MD, Mayo Clinic and Charlotte Pawlyn, BA, MB BChir, PhD, MRCP, FRCPath, The Institute of Cancer Research, The Royal Marsden Hospital NHS Foundation Trust
Disclosures:
Pawlyn: Celgene / BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel support; Amgen: Honoraria; Sanofi: Honoraria, Membership on an entity's Board of Directors or advisory committees; Oncopeptides: Other.
12:00 PM

Sigrun Thorsteinsdottir, MD, PhD1,2, Gauti Kjartan Gislason, MSc1*, Thor Aspelund, PhD3*, Sæmundur Rögnvaldsson, MD4*, Jon Thorir Thorir Oskarsson1*, Iris Petursdottir1*, Jon Kristinn Sigurdsson1*, Gudrun Asta Sigurdardottir1*, Asdis Rosa Thordardottir1*, Brynjar Vidarsson, MD5, Pall Torfi Onundarson, MD5, Bjarni Agnar Agnarsson, MD5*, Margret Sigurdardottir, MD5*, Ingunn Thorsteinsdottir, MD, PhD5*, Isleifur Olafsson, MD, PhD5*, Elias Eythorsson, MD, PhD5*, Asbjorn Jonsson, MD5*, Petros Kampanis, PhD6*, Malin Hultcrantz, MD PhD7, Brian G.M. Durie, MD8, Thorvardur Jon Love, MD, PhD1*, Stephen Harding, PhD9, Ola Landgren, MD10 and Sigurdur Yngvi Kristinsson, MD, PhD1,5

1Faculty of Medicine, University of Iceland, Reykjavik, Iceland
2Department of Hematology, Rigshospitalet, Copenhagen, Denmark
3Public Health Sciences, University of Iceland, Reykjavik, Iceland
4Faculty of Medicine, University of Iceland, Reykjavík, Iceland
5Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
6Binding Site Group Ltd., Birmingham, United Kingdom
7Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
8Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA
9The Binding Site Inc., Birmingham, United Kingdom
10Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami

12:15 PM

Habib El-Khoury, MD1,2, Jean-Baptiste Alberge, PhD1,2,3*, Hadley Barr1,2*, Ciara Murphy1,2*, D.J. Sakrikar, PhD4*, Tara Krause, MSc4*, David Barnidge, PhD4*, Mark Bustoros, MD5, Houry Leblebjian, PharmD, BCOP6*, Annie Cowan, BS1,7*, Maya Davis, BA1,2*, Julia Amstutz1,2*, Jacqueline Perry, MPH1,2*, Cody J. Boehner, BS1,2*, Elizabeth D. Lightbody, PhD1,2*, Tarek H Mouhieddine, MD1,8,9, Romanos Sklavenitis-Pistofidis, MD2,3,10, Mark C Perkins, PhD11*, Stephen Harding, PhD11, Prashant Kapoor, MD12, Clifton C. Mo, MD1,2, David L. Murray, MD, PhD13*, Ivan M. Borrello, MD14, Gad Getz, PhD3,15,16*, Timothy R Rebbeck, PhD1,17*, Catherine R. Marinac, PhD1,17,18 and Irene M. Ghobrial, MD1,2,3,18

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Harvard Medical School, Boston, MA
3Broad Institute of MIT and Harvard, Cambridge, MA
4The Binding Site Inc., Rochester, MN
5Division of Hematology & Medical Oncology, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
6Department of Pharmacy, Dana-Farber Cancer Institute, Boston, MA
7Alix School of Medicine, The Mayo Clinic, Rochester, MN
8Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
9Harvard Medical School, Cambridge, MA
10Department of Medical Oncology, Dana-Farber Cancer Institute, Brookline, MA
11The Binding Site Inc., Birmingham, United Kingdom
12Division of Hematology, Mayo Clinic, Rochester, MN
13Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
14Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
15Center for Cancer Research, Massachusetts General Hospital, Boston, MA
16Cancer Center and Department of Pathology, Massachusetts General Hospital, Boston, MA
17Harvard T.H. Chan School of Public Health, Boston, MA
18The Center for Prevention of Progression of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA

12:30 PM

Giovanni Palladini1, Stefan Schönland2*, Giampaolo Merlini1*, Paolo Milani, MD, PhD1, Arnaud Jaccard3*, Frank Bridoux, MD4*, Meletios A. Dimopoulos, MD5, Sriram Ravichandran, MBBS, MRCP, FRCPath6*, Ute Hegenbart, MD2*, Wilfried Roeloffzen7*, M. Teresa Cibeira, MD, PhD8*, Hermine Agis, MD9, Monique C. Minnema, MD10, Rui Bergantim11*, Roman Hajek, MD, PhD12, Cristina João, MD, PhD, MSc13*, Alexandros Leonidakis, PhD14*, Giorgos Cheliotis, MSc14*, Pieter Sonneveld15, Efstathios Kastritis, MD5* and Ashutosh D. Wechalekar, MBBS MD6

1Amyloidosis Research and Treatment Center, Department of Molecular Medicine, Foundation IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
2Medical Department V, Amyloidosis Center Heidelberg, University of Heidelberg, Heidelberg, Germany
3National Amyloidosis Center and Hematology Unit, CHU Limoges, Limoges, France
4Nephrology Unit, CHU Poitiers, Poitiers, France
5Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
6National Amyloidosis Centre, University College London, London, United Kingdom
7Amyloidosis Centre of Expertise, Department of Internal Medicine, University Medical Center Groningen, Groningen, Netherlands
8Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Clínic, Barcelona, Spain
9Department of Internal Medicine I, Division of Oncology, Medical University Vienna, Vienna, Austria
10Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands
11Department of Hematology, Hospital São João, Porto, Portugal
12Department of Hematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
13Department of Hematology, Champalimaud Centre for the Unknown, Lisbon, Portugal
14Health Data Specialists, Dublin, Ireland
15Cancer Institute, Erasmus MC, Rotterdam, Netherlands

12:45 PM

Sæmundur Rögnvaldsson, MD1*, Elias Eythorsson, MD, PhD2*, Sigrun Thorsteinsdottir, MD, PhD3,4, Brynjar Vidarsson, MD5, Pall Torfi Onundarson, MD5, Bjarni Agnar Agnarsson, MD5*, Margret Sigurdardottir, MD5*, Ingunn Thorsteinsdottir, MD, PhD5*, Isleifur Olafsson, MD, PhD5*, Hrafnhildur Linnet Runolfsdottir, MD, PhD2*, Dadi Helgason, MD, PhD2*, Arna Emilsdóttir, MD2*, Aron H Bjornsson, MD2*, Gudrun Kristjansdottir, MD2*, Asdis Rosa Thordardottir3*, Olafur Skuli Indridason, MD, MHS1,6*, Asbjorn Jonsson, MD7*, Gauti Kjartan Gislason, MSc3*, Andri Olafsson3*, Hlif Steingrimsdottir, MD8*, Petros Kampanis, PhD9*, Malin Hultcrantz, MD PhD10, Brian G.M. Durie, MD11, Stephen Harding, PhD12, Ola Landgren, MD13, Thorvardur Jon Love, MD, PhD3*, Runolfur Palsson, MD1,5* and Sigurdur Y Kristinsson, MD, PhD3,6

1Faculty of Medicine, University of Iceland, Reykjavík, Iceland
2Landspítali - The National University Hospital of Iceland, Reykjavík, Iceland
3Faculty of Medicine, University of Iceland, Reykjavik, Iceland
4Department of Hematology, Rigshospitalet, Copenhagen, Denmark
5Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
6Landspítali - The University Hospital of Iceland, Reykjavik, Iceland
7Akureyri Hospital, Akureyri, Iceland
8Landspitali - National University Hospital of Iceland, Reykjavík, Iceland
9Binding Site Group Ltd., Birmingham, ENG, United Kingdom
10Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
11Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA
12The Binding Site Inc., Birmingham, United Kingdom
13Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami

1:00 PM

Andrew Staron, MD1, Luke Zheng, BS2*, Gheorghe Doros, PhD2*, Lawreen H Connors, PhD3* and Vaishali Sanchorawala, MD4

1Amyloidosis Center, Boston Medical Center, Boston, MA
2Department of Biostatistics, Boston University School of Public Health, Boston, MA
3Amyloidosis Center, Boston University School of Medicine, Boston, MA
4Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA

1:15 PM

Sigurdur Y Kristinsson, MD, PhD1,2, Sæmundur Rögnvaldsson, MD3*, Sigrun Thorsteinsdottir, MD, PhD1,4, Elin Ruth Reed5*, Jon Thorir Thorir Oskarsson1*, Iris Petursdottir1*, Gudrun Asta Sigurdardottir1*, Brynjar Vidarsson, MD6, Pall Torfi Onundarson, MD6, Bjarni Agnar Agnarsson, MD6*, Margret Sigurdardottir, MD6*, Ingunn Thorsteinsdottir, MD, PhD6*, Signy Vala Sveinsdottir, MD PhD7*, Robert Palmason, MD7*, Isleifur Olafsson, MD, PhD6*, Fridbjorn Sigurdsson, MD8*, Asdis Rosa Thordardottir1*, Elias Eythorsson, MD, PhD6*, Asbjorn Jonsson, MD6*, Runolfur Palsson, MD6*, Olafur Skuli Indridason, MD, MHS2*, Gauti Kjartan Gislason, MSc1*, Andri Olafsson1*, Jon Kristinn Sigurdsson1*, Ingigerdur Solveig Sverrisdottir, MD, BSc5*, Maria Soffia Juliusdottir9*, Gudlaug Katrin Hakonardottir5*, Hlif Steingrimsdottir, MD10*, Ragnar Danielsen7*, Petros Kampanis, PhD11*, Malin Hultcrantz, MD PhD12, Brian G.M. Durie, MD13, Stephen Harding, PhD14, Ola Landgren, MD15 and Thorvardur Jon Love, MD, PhD1*

1Faculty of Medicine, University of Iceland, Reykjavik, Iceland
2Landspítali - The University Hospital of Iceland, Reykjavik, Iceland
3Faculty of Medicine, University of Iceland, Reykjavík, Iceland
4Department of Hematology, Rigshospitalet, Copenhagen, Denmark
5University of Iceland, Reykjavik, Iceland
6Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
7Landspitali University Hospital, Reykjavik, Iceland
8Akureyri Hospital, Akureyri, Iceland
9Jessenius faculty of medicine, Martin, Slovakia
10Landspitali - National University Hospital of Iceland, Reykjavík, Iceland
11Binding Site Group Ltd., Birmingham, United Kingdom
12Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
13Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA
14The Binding Site Inc., Birmingham, United Kingdom
15Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami

*signifies non-member of ASH